Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16749278 | 1.00 | IL1B (0.33) | IL1BP2RX7HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL16749578 | 1.00 | IL1B (0.33) | IL1BP2RX7HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL17924665 | 0.87 | HDAC8 (0.34) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL16551816 | 0.87 | HDAC8 (0.34) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL17924755 | 0.87 | HDAC8 (0.34) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL17924713 | 0.85 | ATM (0.35) | IL1BP2RX7HSD17B10ATM | |
| SCHEMBL16749565 | 0.85 | ATM (0.35) | IL1BP2RX7HSD17B10ATM | |
| SCHEMBL16749277 | 0.85 | ATM (0.35) | IL1BP2RX7HSD17B10ATM | |
| SCHEMBL19389999 | 0.85 | IL1B (0.36) | IL1BP2RX7HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL17924657 | 0.84 | NR1H2 (0.38) | IL1BP2RX7HSD17B10CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3071564-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-9498479-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206616-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | IL1B 2216/4885P2RX7 2934/4885HSD17B10 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.